257 related articles for article (PubMed ID: 30069368)
1. Prognostic factors of oligometastatic non-small cell lung cancer: a meta-analysis.
Li S; Zhu R; Li D; Li N; Zhu X
J Thorac Dis; 2018 Jun; 10(6):3701-3713. PubMed ID: 30069368
[TBL] [Abstract][Full Text] [Related]
2. Should aggressive thoracic therapy be performed in patients with synchronous oligometastatic non-small cell lung cancer? A meta-analysis.
Li D; Zhu X; Wang H; Qiu M; Li N
J Thorac Dis; 2017 Feb; 9(2):310-317. PubMed ID: 28275479
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors of oligometastatic non-small-cell lung cancer following radical therapy: a multicentre analysis.
Opitz I; Patella M; Payrard L; Perentes JY; Inderbitzi R; Gelpke H; Schulte S; Diezi M; Gonzalez M; Krueger T; Weder W
Eur J Cardiothorac Surg; 2020 Jun; 57(6):1166-1172. PubMed ID: 32011665
[TBL] [Abstract][Full Text] [Related]
4. Factors Affecting the Survival of Patients with Oligometastatic Non-Small-Cell Lung Cancer: A Meta-Analysis.
Shi Y; Yang J; Yao N; Shao M; Ding W; Jiang W; Sun X
Can Respir J; 2019; 2019():2153170. PubMed ID: 31236146
[TBL] [Abstract][Full Text] [Related]
5. Survival Impact of Aggressive Treatment and PD-L1 Expression in Oligometastatic NSCLC.
Gauvin C; Krishnan V; Kaci I; Tran-Thanh D; Bédard K; Albadine R; Leduc C; Gaboury L; Blais N; Tehfe M; Routy B; Florescu M
Curr Oncol; 2021 Jan; 28(1):593-605. PubMed ID: 33498159
[TBL] [Abstract][Full Text] [Related]
6. Addition of radiotherapy to the primary tumour in oligometastatic NSCLC: A systematic review and meta-analysis.
Petrelli F; Ghidini A; Cabiddu M; Tomasello G; De Stefani A; Bruschieri L; Vitali E; Ghilardi M; Borgonovo K; Barni S; Trevisan F
Lung Cancer; 2018 Dec; 126():194-200. PubMed ID: 30527187
[TBL] [Abstract][Full Text] [Related]
7. A risk stratification scheme for synchronous oligometastatic non-small cell lung cancer developed by a multicentre analysis.
Spaggiari L; Bertolaccini L; Facciolo F; Gallina FT; Rea F; Schiavon M; Margaritora S; Congedo MT; Lucchi M; Ceccarelli I; Alloisio M; Bottoni E; Negri G; Carretta A; Cardillo G; Ricciardi S; Ruffini E; Costardi L; Muriana G; Viggiano D; Rusca M; Ventura L; Marulli G; De Palma A; Rosso L; Mendogni P; Crisci R; De Vico A; Maniscalco P; Tamburini N; Puma F; Ceccarelli S; Voltolini L; Bongiolatti S; Morelli A; Londero F
Lung Cancer; 2021 Apr; 154():29-35. PubMed ID: 33610120
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer.
Fleckenstein J; Petroff A; Schäfers HJ; Wehler T; Schöpe J; Rübe C
BMC Cancer; 2016 Jun; 16():348. PubMed ID: 27255302
[TBL] [Abstract][Full Text] [Related]
9. Might radiation therapy in addition to chemotherapy improve overall survival of patients with non-oligometastatic Stage IV non-small cell lung cancer?: Secondary analysis of two prospective studies.
Su S; Hu Y; Ouyang W; Ma Z; Li Q; Li H; Wang Y; Wang X; Li T; Li J; Chen M; Lu Y; Bai Y; He Z; Lu B
BMC Cancer; 2016 Nov; 16(1):908. PubMed ID: 27871270
[TBL] [Abstract][Full Text] [Related]
10. Radical consolidative treatment provides a clinical benefit and long-term survival in patients with synchronous oligometastatic non-small cell lung cancer: A phase II study.
Arrieta O; Barrón F; Maldonado F; Cabrera L; Corona-Cruz JF; Blake M; Ramírez-Tirado LA; Zatarain-Barrón ZL; Cardona AF; García O; Arén O; De la Garza J
Lung Cancer; 2019 Apr; 130():67-75. PubMed ID: 30885354
[TBL] [Abstract][Full Text] [Related]
11. Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature.
Ashworth A; Rodrigues G; Boldt G; Palma D
Lung Cancer; 2013 Nov; 82(2):197-203. PubMed ID: 24051084
[TBL] [Abstract][Full Text] [Related]
12. Management of Synchronous Extrathoracic Oligometastatic Non-Small Cell Lung Cancer.
Jones GD; Lengel HB; Hsu M; Tan KS; Caso R; Ghanie A; Connolly JG; Bains MS; Rusch VW; Huang J; Park BJ; Gomez DR; Jones DR; Rocco G
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33920810
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of local aggressive lung therapy versus systemic therapy in oligometastatic non-small cell lung cancer: a systematic review and meta-analysis.
Zhang C; Ma N; Zhang Q; Zheng K; Sun C; Tang X; Li X; Zhao J
J Thorac Dis; 2021 Oct; 13(10):5899-5910. PubMed ID: 34795938
[TBL] [Abstract][Full Text] [Related]
14. Improved Overall Survival With Comprehensive Local Consolidative Therapy in Synchronous Oligometastatic Non-Small-Cell Lung Cancer.
Mitchell KG; Farooqi A; Ludmir EB; Corsini EM; Zhang J; Sepesi B; Vaporciyan AA; Swisher SG; Heymach JV; Zhang J; Gomez DR; Antonoff MB
Clin Lung Cancer; 2020 Jan; 21(1):37-46.e7. PubMed ID: 31447303
[TBL] [Abstract][Full Text] [Related]
15. KRAS mutation as a prognostic factor and predictive factor in advanced/metastatic non-small cell lung cancer: A systematic literature review and meta-analysis.
Goulding RE; Chenoweth M; Carter GC; Boye ME; Sheffield KM; John WJ; Leusch MS; Muehlenbein CE; Li L; Jen MH; Rojubally A; Jansen J; Druyts E
Cancer Treat Res Commun; 2020; 24():100200. PubMed ID: 32750661
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Tumor Vaccines and Cellular Immunotherapies in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Dammeijer F; Lievense LA; Veerman GD; Hoogsteden HC; Hegmans JP; Arends LR; Aerts JG
J Clin Oncol; 2016 Sep; 34(26):3204-12. PubMed ID: 27432922
[TBL] [Abstract][Full Text] [Related]
17. Insulin-like growth factor receptor 1 (IGF1R) expression and survival in non-small cell lung cancer patients: a meta-analysis.
Zhao S; Qiu Z; He J; Li L; Li W
Int J Clin Exp Pathol; 2014; 7(10):6694-704. PubMed ID: 25400749
[TBL] [Abstract][Full Text] [Related]
18. Benefit of adjuvant chemotherapy for patients with stage IB non-small cell lung cancer: a systematic review and meta-analysis.
Wang X; Chen D; Wen J; Mao Y; Zhu X; Fan M; Chen Y
Ann Transl Med; 2021 Sep; 9(18):1430. PubMed ID: 34733982
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance and role of lymphatic vessel invasion as a major prognostic implication in non-small cell lung cancer: a meta-analysis.
Wang J; Wang B; Zhao W; Guo Y; Chen H; Chu H; Liang X; Bi J
PLoS One; 2012; 7(12):e52704. PubMed ID: 23285161
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
Qin K; Hou H; Liang Y; Zhang X
BMC Cancer; 2020 Apr; 20(1):328. PubMed ID: 32299384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
